We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 30.68+1.7%Jun 5 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Fitzhughlaw who wrote (52460)9/12/2019 9:48:03 AM
From: JohnBeach8 Recommendations

Recommended By

and 3 more members

   of 56638
In addition to what you quoted of the FDA's guidance, it continues to say that one of the ways to demonstrate substantial improvement is:

"The new drug has an important safety advantage that relates to serious adverse reactions (e.g., those that may result in treatment interruption) compared with available therapies and has similar efficacy."

That would appear to be 132's path to BTD.

FWIW, statistically the chance is not great: In the first 3 quarters of the federal fiscal year beginning Oct 1 2018, the FDA received 118 BTD requests. 36 were granted, 46 denied, and the rest are pending. On the other hand, in mUC, 9 drugs since 2014 have received BTD.

Considering the way things are moving toward targeted therapies, I think targeting Trop2 in mUC would guarantee 132's chance at BTD and position it better vs EV. Trop2 is expressed in 83% of mUC. Eliminating those 17% of patients that wont respond will elevate the ORR on par with EV. And it would be better for patients. I wonder if they collected tissue samples for a post hoc look (they are doing that in the prostate study).

Then again, what company schedules an investor event if the data isn't impressive?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext